The Combination of the PARP Inhibitor Olaparib and the ATR Inhibitor VE-821 Selectively Targets ATM-Deficient Lung Cancer Cells

被引：0
|
作者：
Jette, N. [1 ]
Radhamani, S. [1 ]
Arthur, G. [1 ]
Ye, R. [1 ]
Goutam, S. [1 ]
Boylos, A. [1 ]
Petersen, L. [1 ]
Bose, P. [1 ]
Bebb, G. [1 ]
Lees-Miller, S. [1 ]
机构：
[1] Univ Calgary, Calgary, AB, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Olaparib; VE-821; ATM;
D O I：
10.1016/j.jtho.2019.08.1192
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.14-41
引用
收藏
页码：S570 / S571
页数：2
相关论文
共 50 条
  • [31] Inhibition of ATR overcomes the PARP inhibitor resistance of BRCA-deficient cancer cells
    Yazinski, A.
    Zou, Lee
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 17 - 17
  • [32] RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
    Min, Ahrum
    Im, Seock-Ah
    Yoon, Young-Kwang
    Song, Sang-Hyun
    Nam, Hyun-Jin
    Hur, Hyung-Seok
    Kim, Hwang-Phill
    Lee, Kyung-Hun
    Han, Sae-Won
    Oh, Do-Youn
    Kim, Tae-You
    O'Connor, Mark J.
    Kim, Woo-Ho
    Bang, Yung-Jue
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (06) : 865 - 877
  • [33] ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
    Wilson, Zena
    Odedra, Rajesh
    Wallez, Yann
    Wijnhoven, Paul W. G.
    Hughes, Adina M.
    Gerrard, Joe
    Jones, Gemma N.
    Bargh-Dawson, Hannah
    Brown, Elaine
    Young, Lucy A.
    O'Connor, Mark J.
    Lau, Alan
    CANCER RESEARCH, 2022, 82 (06) : 1140 - 1152
  • [34] Investigating the effect of replication stress and other phenotypic factors as determinants of sensitivity to single agent ATR inhibitor, VE-821 in ovarian cancer cell lines
    Bradbury, A.
    King, D.
    Bryant, H.
    Zenke, F.
    Drew, Y.
    Curtin, N.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E32 - E32
  • [35] PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells
    Changjiang Qin
    Zhiyu Ji
    Ertao Zhai
    Kaiwu Xu
    Yijie Zhang
    Quanying Li
    Hong Jing
    Xiaoliang Wang
    Xinming Song
    Cell Death & Disease, 13
  • [36] Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.
    Wethington, Stephanie L.
    Shah, Payal D.
    Martin, Lainie P.
    Tanyi, Janos Laszlo
    Latif, Nawar A.
    Morgan, Mark Aloysuis
    Torigian, Drew A.
    Pagan, Cheyenne
    Rodriguez, Diego
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Le-Ming
    Smith, Simon
    Dean, Emma
    Armstrong, Deborah Kay
    Gaillard, Stephanie
    Simpkins, Fiona
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells
    Qin, Changjiang
    Ji, Zhiyu
    Zhai, Ertao
    Xu, Kaiwu
    Zhang, Yijie
    Li, Quanying
    Jing, Hong
    Wang, Xiaoliang
    Song, Xinming
    CELL DEATH & DISEASE, 2022, 13 (05)
  • [38] 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells (vol 16, pg 725, 2016)
    Hong, Ruoxi
    Ma, Fei
    Zhang, Weimin
    Yu, Xiying
    Li, Qing
    Luo, Yang
    Zhu, Changjun
    Xu, Binghe
    Jiang, Wei
    BMC CANCER, 2016, 16
  • [39] Growth inhibitory effect of PARP inhibitor olaparib in gastric cancer cells
    Im, Seock-Ah
    Min, Ahrum
    Hur, Hyung-Seok
    Yoon, Young-Kwang
    Song, Sang Hyun
    Riches, Lucy
    Knights, Charlotte
    Han, Sae-Won
    Oh, Do-Youn
    Wombwell, Helen
    Kim, Tae-You
    Gu, Yi
    Lau, Alan
    Bang, Yung-Jue
    O'Connor, Mark
    CANCER RESEARCH, 2010, 70
  • [40] Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
    Osoegawa, Atsushi
    Gills, Joell J.
    Kawabata, Shigeru
    Sugio, Kenji
    Dennis, Phillip A.
    CANCER RESEARCH, 2014, 74 (19)
12345